The BIO International Convention 2025 was held in Boston, MA from June 16-19 It is the largest event for biotechnology with 20,000 industry leaders in attendance, sharing the latest advancements in the industry. The most popular topics included:
→ Biointron’s Highlighted Points:
1. Oncology
Oncology investment is increasingly focused on emerging therapeutic modalities, including antibody-drug conjugates, cell therapies, radiopharmaceuticals, and cancer vaccines, which now account for 50% of recent biotech acquisitions, reflecting a major shift from the historical dominance of small molecules and monoclonal antibodies. This trend, informed by five years of pipeline and deal data, highlights how venture funding, M&A, and IPO activity are aligning with a more diverse and innovation-driven oncology landscape.
The oncology field is advancing rapidly with innovative breakthroughs, from next-generation ADCs to in vivo immunotherapies and strategic combinations, designed to tackle both common and rare cancers by attacking the disease from multiple angles and redefining the standard of care.
2. AI and Digital Health
Investments in accelerated computing, large-scale data generation, and model-first strategies are driving innovation in computational drug design, with foundation models (FMs) enabling the integration of massive multimodal datasets to uncover novel drug targets. Generative AI is being applied to design small molecules, antibodies, and other therapeutic modalities, significantly reducing R&D costs and shortening timelines from target identification to IND application.
Industry benchmarks demonstrate real-world progress in applying these technologies to streamline drug development, while addressing persistent bottlenecks such as data quality, model interpretability, and integration into existing discovery pipelines.
Biopharma is entering a new era as companies create large-scale “digital twins” of the natural world to overcome the limitations of traditional, narrow datasets, enabling foundational AI models to uncover hidden biological signals and design novel genomes and proteins.
3. Next Generation Biotherapeutics
Conditionally active biologics represent a new class of safer and more efficacious treatments that will directly benefit patients with devastating diseases. These drugs regulate their own activity, making them inactive in circulation and enabling them to switch to an active conformation when bound to a specific marker.
4. Business
Discussion surrounding when novel drug modalities, e.g. ADCs, PROTACs, and AI-driven platforms become partnerable, how patient need influences decision-making, and the strategic data packages and market conditions that shape early collaborations and de-risk investment in unproven but high-potential technologies.
Thank you to everyone who visited our booth at BIO 2025 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
